One of the first German pharmaceutical and biotech companies
biosyn Arzneimittel GmbH has been committed to advancing healthcare and improving lives since the founding of the company in 1984 in Fellbach, Germany. Today, biosyn has over 70 employees with the pharmaceutical expertise necessary to provide healthcare services to over 20 countries globally. biosyn has subsidiaries in 3 locations: Liechtenstein, Austria, and the USA.
Our focus is on developing – and producing – innovative GMP-compliant medicines geared to the areas of intensive care, oncology, and endocrinology. We do so safely and effectively with world-class GMP facilities in Fellbach and California.
Forerunner of sustainable therapeutics
We believe that novel therapeutics' future lies in sustainability, and it shows in our manufacturing processes. biosyn extracts hemolymph from the California keyhole limpet, Megathura crenulate, by a non-lethal puncture – and processes it to a pharmaceutical-grade quality immunocynanin. This active ingredient is traditionally marketed under the name IMMUCOTHEL® to treat bladder cancer and VACMUNE®, a carrier molecule for therapeutic vaccines. Promisingly, in recent years, hemocyanin is also showing potential therapeutic benefit in immunology.
Deeply committed to research and development
At biosyn, we believe that science leads the way to tomorrow's breakthrough therapies. That's why we're committed to carrying out – and investing in – new methods of treatment. We invest up to 25% of our revenues back into our R&D pipelines. biosyn has offered support (by providing the drug selenase® or administrative assistance) to over 50% of clinical trials studying selenium's effects on medical treatment of sepsis, oncology, reperfusion, and cardiac surgery, amongst other diseases, in the last 15 years.
Collaborate with experts at every stage
To ensure that scientific insights are applied to clinical practice, we collaborate with healthcare experts at every stage – from early discovery to market access. biosyn attends national and international conferences organized by professional medical societies, assesses international scientific publications, and communicates this information to physicians and research institutions worldwide.
Open, engaged, and customer-oriented corporate culture – always
As a mid-sized family enterprise, biosyn understands the importance of creating an environment that will foster our team’s responsiveness to customers’ needs – keeping us a step ahead of the industry and benefitting patients at large, worldwide.
These efforts are led by
Thomas Stiefel, D.Sc.
Majority shareholder of biosyn Arzneimittel GmbH and biosyn Corporation
Thomas' in elucidating the metabolic behavior of trace elements was first lit during his studies of chemistry and biochemistry. After that, research work at the Max Planck Institute for Metals Research in Stuttgart, combined with R&D management in the pharmaceutical industry, equipped him with the knowledge required to initiate biosyn’s pharmaceutical innovation.
His steadfast drive to advance science and medicine is reflected in his many international patents, distinguished publications, educational lectures, and active memberships in relevant societies like the Chemical Industry Association (VCI), Society of Minerals and Trace Elements (GSM), and SepNet.
Ortwin Kottwitz
Managing Director of biosyn Arzneimittel GmbH
Trained in chemical engineering, Ortwin has managed the production, development, and manufacturing of pharmaceuticals, cosmetics, and injection formulations in the pharmaceutical industry, since 1975. Naturally, he managed product development when biosyn was founded.
Sharing Dr. Stiefel’s passion for and dedication to research, Ortwin Kottwitz is also responsible for supervising biosyn's many research projects. For instance, he designed and constructed both of the complex GMP-compliant production facilities in both Fellbach and at the biosyn Corporation in Carlsbad, California.
